Fresenius Kabi and Sandoz to Co-Develop HESylated Protein

August 31, 2006
BioPharm International Editors

Fresenius Kabi (Bad Homburg, Germany, www.fresenius-kabi.com) and Sandoz, (Holzkirchen, Germany, www.sandoz.com), have entered into a partnership to develop a second-generation version of an un-named Sandoz recombinant protein using Fresenius Kabi's "HESylation" technology.

Fresenius Kabi (Bad Homburg, Germany, www.fresenius-kabi.com) and Sandoz, (Holzkirchen, Germany, www.sandoz.com), have entered into a partnership to develop a second-generation version of an un-named Sandoz recombinant protein using Fresenius Kabi’s “HESylation” technology. Based on hydroxyethyl starch (HES), the technology is used to improve key drug parameters such as absorption, metabolization, half-life, and water solubility.

Related Content:

News